ストックスクリーナーアプリを入手
4.65
2.11%
-0.10
アフターアワーズ：
4.64
-0.01
-0.22%
Passage Bio Inc (PASG) 最新ニュース
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - Stocktwits
Passage Bio stock holds steady as investors weigh gene therapy pipeline and recent losses - AD HOC NEWS
Passage Bio Amends Remix Merger, Private Financing Terms - TipRanks
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE - TradingView
Remix deal would leave Passage Bio (NASDAQ: PASG) investors a small slice of the combined company - Stock Titan
Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop - Fierce Biotech
Passage Bio stock reacts to reverse split as investors watch next steps - AD HOC NEWS
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits
Passage (PASG) Earnings Update: EPS Exceeds Its Estimate in the Latest Reading; Trading Move: Shares Fall 0.22% in the Current UpdateTech Earnings Analysis - vinanet.vn
GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opportunity - openPR.com
Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace
Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership - Stock Titan
Passage Bio | SCHEDULE 13G/A: Others - Moomoo
PASG Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2% Share GainSpecial Dividend Alert - Vinanet
Passage Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Passage Bio Q2 net loss narrows 16.67% to $7.82 million - Bitget
Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary - TradingView
PASG: Pending merger with Remix is vital as cash dwindles and operations wind down - TradingView
Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms - Stock Titan
Passage Bio Inc expected to post a loss of $2.65 a shareEarnings Preview - TradingView
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CYBR.O Forecast — Price Prediction for 2026. Should I Buy CYBR.O? - Intellectia AI
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
REPX Q1 2026 Earnings: Deep EPS Miss Delivers -369.75% Surprise as Shares Gain 2.24%Revenue Breakdown Analysis - vinanet.vn
PASG Q2'26 Earnings: EPS estimate is (2.65) USD - TradingView
Passage Bio Inc. (PASG) Slips 3% as Shares Approach Key Support LevelHigh Volume Stocks - dars.gov.et
Passage Bio Inc (PASG) Cash Flow - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Income Statement - tradingkey.com
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Balance Sheet - TradingKey
PASG|Passage Bio Inc|Price:4.570|Chg%:-0.370 - TradingKey
PASG|Passage Bio Inc|Price:4.940|Chg%:+0.040 - TradingKey
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Passage Bio, Inc. Revenue Breakdown – NASDAQ:PASG - TradingView
Passage Bio (PASG) Q1 2026 Earnings: Narrowed Loss Exceeds Expectations Amid Continued Pipeline ProgressProfit Recovery Report - dars.gov.et
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRNX, SLP, NCSM, and PASG - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG - Finansavisen
PASG Q2'26 Earnings: revenue estimate is 0 USD - TradingView
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline in Pre-Revenue PhaseFinal Results - vinanet.vn
Passage Bio (PASG) to merge with Remix in $100M-backed oncology deal - Stock Titan
Form 4 Passage Bio Inc For: 22 July By Investing.com - Investing.com Nigeria
PASG: Merger creates a leading RNA-focused biotech with REM-422 poised for ACC and AML impact - TradingView
Passage Bio (NASDAQ: PASG) to merge with Remix Therapeutics in $346M stock deal - Stock Titan
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-Than-Expected Loss as Cost Controls SurpriseEarnings Cycle Outlook - dars.gov.et
Passage Bio Inc. (PASG) Surges 5.74% as Stock Approaches Key Resistance LevelMoving Average Crossovers - dars.gov.et
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):